Agenus Inc. (NASDAQ:AGEN) reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $7.24 and last traded at $6.98, with a volume of 1,308,131 shares trading hands. The stock had previously closed at $6.77.

A number of equities research analysts have recently issued reports on the company. Zacks Investment Research upgraded Agenus from a “sell” rating to a “hold” rating in a research note on Tuesday, July 5th. Maxim Group reiterated a “buy” rating and issued a $7.00 target price on shares of Agenus in a research note on Thursday, July 28th. Jefferies Group reiterated a “buy” rating on shares of Agenus in a research note on Tuesday, August 23rd. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Agenus in a research note on Sunday, July 31st. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $10.25.

The company’s 50-day moving average price is $6.15 and its 200 day moving average price is $4.63. The firm’s market capitalization is $601.87 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/agenus-inc-agen-hits-new-52-week-high-at-7-24.html

Agenus (NASDAQ:AGEN) last issued its earnings results on Thursday, July 28th. The company reported ($0.33) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.34) by $0.01. The business earned $6.59 million during the quarter, compared to analysts’ expectations of $5.12 million. Agenus had a negative return on equity of 138.27% and a negative net margin of 328.53%. On average, analysts forecast that Agenus Inc. will post ($1.27) EPS for the current fiscal year.

In other news, Director Ulf Wiinberg acquired 30,000 shares of Agenus stock in a transaction that occurred on Tuesday, September 6th. The stock was purchased at an average price of $6.29 per share, with a total value of $188,700.00. Following the completion of the transaction, the director now owns 30,000 shares in the company, valued at $188,700. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 7.60% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in AGEN. venBio Select Advisor LLC boosted its stake in Agenus by 9.2% in the first quarter. venBio Select Advisor LLC now owns 2,400,868 shares of the company’s stock worth $9,988,000 after buying an additional 201,731 shares during the last quarter. Creative Planning boosted its stake in Agenus by 2.8% in the second quarter. Creative Planning now owns 64,171 shares of the company’s stock worth $260,000 after buying an additional 1,762 shares during the last quarter. BlackRock Institutional Trust Company N.A. boosted its stake in Agenus by 1.0% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 1,778,629 shares of the company’s stock worth $7,399,000 after buying an additional 17,006 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Agenus by 2.9% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 983,924 shares of the company’s stock worth $3,985,000 after buying an additional 28,006 shares during the last quarter. Finally, Squarepoint Ops LLC boosted its stake in Agenus by 19.1% in the first quarter. Squarepoint Ops LLC now owns 76,700 shares of the company’s stock worth $319,000 after buying an additional 12,300 shares during the last quarter. 40.63% of the stock is owned by hedge funds and other institutional investors.

About Agenus

Agenus Inc (Agenus) is an immuno-oncology company. The Company is engaged in discovering and developing treatments for patients with cancer. Its approaches are driven by platforms and programs, which include antibody discovery platform, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage and AutoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

5 Day Chart for NASDAQ:AGEN

Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.